文献速递淋巴瘤

儿童伯基特淋巴瘤单细胞转录组学揭示瘤内异质性与治疗耐药标志物

Single-cell transcriptomics of pediatric Burkitt lymphoma reveals intra-tumor heterogeneity and markers of therapy resistance.
PubMed 文献 · Leukemia · 2024-10-18

该研究对儿童EBV阴性伯基特淋巴瘤(BL)诊断标本进行单细胞转录组分析,比较治疗应答者(R)与无应答者(NR)。结果发现肿瘤具有患者特异性特征及共享亚群,非肿瘤成分中免疫细胞为主、成纤维细胞在NR中富集;TPM2在NR的转录和蛋白水平均显著升高,基于TPM2表达分层与预后显著相关且独立于TP53突变。

要点

  • 儿童EBV阴性BL诊断标本单细胞转录组显示瘤内转录异质性。
  • 非肿瘤成分以免疫细胞为主,成纤维细胞在治疗无应答者中富集。
  • TPM2在无应答者转录和蛋白水平均显著升高,其表达分层与预后相关且独立于TP53突变。

核心结论

  • 儿童伯基特淋巴瘤呈现转录异质性,TPM2等为治疗耐药的候选生物标志物。

研究设计与样本

  • 对儿童EBV阴性伯基特淋巴瘤诊断标本进行单细胞转录组分析,比较治疗应答者(R)与无应答者(NR)。

主要发现

  • 非肿瘤成分以免疫细胞为主,成纤维细胞少量存在且在NR中富集。
  • 肿瘤显示患者特异性特征及与细胞周期、信号通路和细胞起源特征相关的共享亚群。
  • TPM2在NR中转录和蛋白水平均显著高于R。
  • 基于诊断时TPM2表达的患者分层与预后显著相关,且独立于TP53突变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Burkitt lymphoma (BL) is the most frequent B-cell lymphoma in pediatric patients. While most patients are cured, a fraction of them are resistant to therapy. To investigate BL heterogeneity and the features distinguishing therapy responders (R) from non-responders (NR), we analyzed by single-cell (sc)-transcriptomics diagnostic EBV-negative BL specimens. Analysis of the non-tumor component revealed a predominance of immune cells and a small representation of fibroblasts, enriched in NR. Tumors displayed patient-specific features, as well as shared subpopulations that expressed transcripts related to cell cycle, signaling pathways and cell-of-origin signatures. Several transcripts were differentially expressed in R versus NR. The top candidate, Tropomyosin 2 (TPM2), a member of the tropomyosin actin filament binding protein family, was confirmed to be significantly higher in NR both at the transcript and protein level. Stratification of patients based on TPM2 expression at diagnosis significantly correlated with prognosis, independently of TP53 mutations. These results indicate that BL displays transcriptional heterogeneity and identify candidate biomarkers of therapy resistance.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Corinaldesi C, Holmes AB, Martire G, et al. Single-cell transcriptomics of pediatric Burkitt lymphoma reveals intra-tumor heterogeneity and markers of therapy resistance. Leukemia. 2024. PMID: 39424708. doi:10.1038/s41375-024-02431-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。